Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026
Inotiv (NASDAQ: NOTV) will report fiscal 2026 first quarter results for the period ended December 31, 2025, on Monday, February 9, 2026, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inotiv (NASDAQ: NOTV) will report fiscal 2026 first quarter results for the period ended December 31, 2025, on Monday, February 9, 2026, before the market opens.
The company will host a conference call the same day at 8:30 a.m. Eastern Time with domestic and international dial‑in access and a live webcast. An online replay will be available in the Investors section of Inotiv's website.
Details
News Market Reaction – NOTV
On Feb 4, the day this news came out, NOTV closed 6.83% below the previous close.
Data tracked by StockTitan Argus for the Feb 4 session.
Key Figures
- Earnings release date
- February 9, 2026
- Fiscal 2026 Q1 results scheduled before market open
- Quarter end date
- December 31, 2025
- Fiscal 2026 first quarter period end
- Conference call time
- 8:30 a.m. Eastern Time
- Start time for fiscal 2026 Q1 call
- Domestic dial-in
- 1-800-445-7795
- U.S. access number for conference call
- International dial-in
- 1-785-424-1699
- International access number for conference call
Previous Conferences,earnings date Reports
-
Announced timing of FY2025 Q4 and full-year results and conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- 1-800-445-7795 (Domestic)
- 1-785-424-1699 (International)
- INOTIV (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1750994&tp_key=1585804d3b
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/events-and-presentations/default.aspx
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the Company’s ability to comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the U.S. Department of Justice and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the Company's assessment of its cybersecurity incident, ongoing or potential impacts, and efforts of the Company related to the incident, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | LifeSci Advisors | |
| Beth A. Taylor, Chief Financial Officer | Steve Halper | |
| (765) 497-8381 | (646) 876-6455 | |
| beth.taylor@inotiv.com | shalper@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.